Trial · NCT04064346
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Serum Alanine Aminotransferase (ALT) Levels >3 × the Upper Limit of Normal (ULN) - Part 1 | Lixivaptan | 0 | Participants | ||
| Number of Participants With Serum Alanine Aminotransferase (ALT) Levels >3 × the Upper Limit of Normal (ULN) - Part 1 | Placebo | 1 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Lixivaptan Titration Period in Part 1 | Lixivaptan Titration Period Participants | 3 | Participants | ||
| Number of Participants With TEAEs After Randomization in Part 1 | Lixivaptan | 1 | Participants | ||
| Number of Participants With TEAEs After Randomization in Part 1 | Placebo | 1 | Participants | ||
| Number of Participants With Potentially Clinically Important Clinical Laboratory Findings During the Lixivaptan Titration Period in Part 1 | Lixivaptan Titration Period Participants | 0 | Participants | ||
| Number of Participants With Potentially Clinically Important Clinical Laboratory Findings After Randomization in Part 1 | Lixivaptan | 0 | Participants | ||
| Number of Participants With Potentially Clinically Important Clinical Laboratory Findings After Randomization in Part 1 | Placebo | 0 | Participants | ||
| Number of Participants With Potentially Clinically Important Vital Signs Findings During the Lixivaptan Titration Period in Part 1 | Lixivaptan Titration Period Participants | 0 | Participants | ||
| Number of Participants With Potentially Clinically Important Vital Signs Findings After Randomization in Part 1 | Lixivaptan | 0 | Participants | ||
| Number of Participants With Potentially Clinically Important Vital Signs Findings After Randomization in Part 1 | Placebo | 0 | Participants | ||
| Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Findings During the Lixivaptan Titration Period in Part 1 | Lixivaptan Titration Period Participants | 0 | Participants | ||
| Number of Participants With Potentially Clinically Significant 12-lead ECG Findings After Randomization in Part 1 | Lixivaptan | 0 | Participants | ||
| Number of Participants With Potentially Clinically Significant 12-lead ECG Findings After Randomization in Part 1 | Placebo | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04064346/results